Engflag

Laritol

Quick links to important sections

Laritol

There is no image.

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Laritol

Quick Facts

Property Description
Active Ingredient Loratadine
Form Oral tablet, Oral syrup, Rapidly disintegrating tablet
Pharmacological Class Second-Generation Antihistamine
General Purpose Provides anti-allergic relief
Origin Synthetic organic compound

What is Laritol?

Laritol is a medication defined by its active ingredient, Loratadine, which is classified as a highly selective second-generation antihistamine. This synthetic compound is used to relieve common discomforts associated with allergic reactions by acting as an inverse agonist or antagonist at the peripheral histamine H1-receptor. Loratadine is utilized for its ability to manage allergic symptoms effectively.

This agent is specifically a tricyclic piperidine derivative whose chemical structure restricts its ability to cross the blood-brain barrier easily. This differentiating feature is why it is consistently categorized as a non-sedating antihistamine, offering a distinct advantage over older, first-generation agents. Loratadine maintains its therapeutic effect for approximately 24 hours, supporting once-daily use.

Composition, Available Forms, and General Therapeutic Purpose

The medicine is typically formulated as a single-ingredient product for oral administration, available as a standard tablet, capsule, oral syrup, or specialized rapidly disintegrating tablet. This availability in multiple forms—which utilize basic solid excipients or an aqueous vehicle—ensures appropriate use across various patient demographics, including children and adults. The medicine's core purpose is to provide sustained anti-allergic relief by counteracting the underlying physiological cause of histamine-mediated discomfort, such as the persistent itching or sneezing typical of environmental allergies.

Regulatory References

  1. Loratadine - StatPearls - NCBI Bookshelf

What side effects are possible with Laritol?

Possible Side Effects and Safety Information

Laritol (Loratadine) is associated with a defined safety profile derived from regulatory documents. Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOCs). The most commonly reported adverse reactions in adults and adolescents include headache, somnolence (drowsiness), fatigue, and dry mouth. These effects are officially categorized as Common.

Less frequent effects, classified as Uncommon, may involve insomnia, an increase in appetite, and gastrointestinal reactions such as gastritis. Serious adverse reactions are reported in the Very Rare category and include anaphylaxis, angioedema, and seizures. The official regulatory scope also documents potential effects on the Nervous System and Hepatobiliary Disorders (abnormal hepatic function).

Specific safety considerations are noted for certain populations. Patients with severe hepatic impairment are advised to use the medication with caution due to potential differences in drug clearance. For pediatric patients (2 to 12 years of age), regulatory data indicates a higher occurrence of effects such as nervousness and wheezing. Laritol is contraindicated for individuals with known hypersensitivity to Loratadine or any other component of the formulation. Additionally, co-administration with certain inhibitors of the CYP3A4 or CYP2D6 enzyme systems may increase the risk of adverse reactions.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information for Laritol

In the event of an overdose with Laritol (Loratadine), immediate medical attention must be sought, and emergency services or a Poison Control Center should be contacted right away. Regulatory documents define the required response as urgent and necessary.

Overdose may present with documented clinical manifestations affecting the central nervous system and the cardiovascular system. Officially recognized signs include excessive somnolence (drowsiness), headache, and a rapid heartbeat known as tachycardia. In children, specific manifestations have included palpitations and extrapyramidal signs.

Official Management and Monitoring

Management of over-exposure is primarily symptomatic and supportive treatment, as regulatory sources state that no specific antidote is known for Loratadine. Due to documented post-marketing risks, close cardiac function monitoring (e.g., electrocardiogram) is required following an overdose for an appropriate period of observation.

Procedural interventions described in official labeling may include gastric lavage (stomach wash) and the administration of activated charcoal as a slurry with water to limit systemic absorption. It is also noted in regulatory information that Loratadine is not effectively removed by haemodialysis.

Therapeutic Uses of Laritol

What Laritol treats: Main Uses and Benefits

Laritol (Loratadine) is commonly used to help with symptoms related to allergic or irritative states, providing supportive relief when symptoms interfere with daily functioning. It is utilized for managing symptom clusters associated with allergic rhinitis and urticaria.

Relief of Nasal and Ocular Allergy Symptoms

This medication helps address symptom clusters that may interfere with daily comfort during episodes of Allergic Rhinitis (hay fever), whether seasonal or perennial. It is applied when symptoms create noticeable physiological strain, such as persistent sneezing, runny nose, itchy eyes, and watery eyes. It provides supportive relief that helps with symptom fluctuations.

“Applied in contexts where additional symptomatic support is needed, Laritol is used for managing the distressing pattern of upper airway and ocular discomfort.”

Management of Hives and Widespread Skin Itching

Laritol is also relevant in conditions involving episodic or fluctuating manifestations like Urticaria and general skin allergies. It is commonly used to help with managing symptoms that interfere with daily comfort, specifically helping to control intense skin itching (pruritus) and the formation of welts or wheals. This may assist with maintaining functional stability and contributes to easing the overall symptom load during periods of heightened discomfort.

Quick Fact: Symptomatic Support for Allergic Conditions

Category Therapeutic Benefit
Primary Indication Allergic Rhinitis (Seasonal & Perennial)
Key Symptoms Sneezing, Runny Nose, Skin Itching (Pruritus), Hives
Scenario Relevance Applied during phases when symptoms become more noticeable
Patient Benefit Supports general well-being during symptomatic phases

Regulatory References

  1. Loratadine: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Laritol — Official Regulatory Information

Eligibility Scope

Classification Rule (Official Labeling)
Populations Allowed Adults and adolescents (ge 12 years) and children ge 2 years of age (using appropriate liquid forms).
Contraindications Patients with known hypersensitivity to loratadine or any formulation excipients must not use the medicine.
Use Not Established Safety and efficacy have not been established for children under 2 years of age.
Not Recommended Use is not recommended in breastfeeding women, as loratadine is excreted in breast milk.

Condition-Specific Eligibility Rules

Condition Regulatory Restriction
Severe Hepatic Impairment Use requires caution; a lower initial dose is recommended due to reduced clearance.
Excipient-Based Patients with Phenylketonuria (PKU) must avoid specific dosage forms containing phenylalanine.

Connection to the Overall Eligibility Profile

Regulatory documents define eligibility through absolute contraindications (hypersensitivity) and conditional use restrictions applied to specific populations, including those with impaired liver function or age below the established minimum of two years. This framework ensures that use is limited to groups with demonstrated safety or where risks can be managed under strict regulatory guidance.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Laritol (Loratadine) is primarily metabolized in the liver, and its exposure can be significantly affected by medicines that influence the activity of specific metabolic enzymes, notably Cytochrome P450 (CYP) enzymes and drug transporters.

Documented Pharmacokinetic Interactions

Co-administration of Laritol with medicines that are known inhibitors of drug metabolism can lead to a marked increase in the plasma concentrations of both Laritol and its active metabolite, desloratadine. This is considered a clinically significant pharmacokinetic interaction documented in regulatory labeling.

Co-administered Medicine or Class Effect on Laritol/Desloratadine Exposure
Strong CYP3A4 Inhibitors (e.g., Ketoconazole) Significantly Increased Plasma Concentrations
CYP2D6 Inhibitors (e.g., Cimetidine, Erythromycin) Increased Plasma Concentrations

Practical Implications and Restrictions

Official regulatory documentation notes that the use of strong inhibitors of CYP3A4 and/or CYP2D6 should be approached with caution. The resulting increases in systemic drug exposure, while not consistently associated with changes in the established safety profile in clinical trials, warrant assessment for potential risk when these combinations are used. No explicit timing or spacing requirements are stated in the official interaction profile, but the need for increased monitoring or regimen adjustment when combining with documented inhibitors is implied by the classification of these as clinically relevant interactions.

Mechanism of Action

Laritol (loratadine) acts by selectively engaging key biological pathways to alter signaling dynamics related to specific natural chemical mediators.

Targeting the Peripheral Histamine H1 Pathway

The drug functions as a selective inverse agonist to block the peripheral histamine H1 receptors, preventing the binding and subsequent activation by endogenous histamine in tissues like the skin and respiratory tract. This molecular interaction modifies the initial steps of the inflammatory signaling cascade.

Mechanism and Physiological Consequence

The mechanistic action of blocking the H1 receptor directly interrupts the histamine-driven cascade that results in the expansion of local blood vessels and increased fluid leakage (vascular permeability). This interference with the inflammatory signaling sequence leads to predictable physiological adjustments within the targeted peripheral pathways.

Absence of Central Nervous System Action

The drug is characterized by a minimal ability to cross the blood-brain barrier, limiting its interaction to H1 receptors found primarily in the periphery. This targeted molecular profile allows the drug to modulate the peripheral inflammatory process with minimal interaction with central nervous system functions.

Dosage and Administration Information

Administration Scope

Laritol (Loratadine) is exclusively administered via the oral route in various forms, including tablets, rapidly-disintegrating tablets, and oral solution or syrup. The medication is taken as a fixed, once-daily schedule for all approved uses. This standardized regimen is possible because the drug's effect lasts in excess of 24 hours. Administration may occur without regard to mealtime.

Labeled Dosing Regimens

The standard dose varies by age group and weight:

Age Group Standard Once-Daily Dose Special Adjustment for Organ Impairment
Adults and Children 6 years and older 10 mg once daily 10 mg every other day*
Children 2 to 5 years 5 mg once daily 5 mg every other day*

*This adjusted regimen is indicated for patients with severe hepatic impairment or severe renal impairment (glomerular filtration rate < 30 mL/min) to account for reduced drug clearance. The maximum labeled dose must not be exceeded in a 24-hour period.

Procedural and Contextual Instructions

For liquid forms, the dose must be measured accurately using the appropriate dosing device (such as the enclosed spoon or cup) to ensure the correct volume is delivered. Rapidly-disintegrating tablets are designed to dissolve on the tongue and can be swallowed with or without water.

A specific procedural constraint exists: the administration of Laritol is typically discontinued at least 48 hours prior to allergy skin testing to prevent the antihistamine from interfering with the diagnostic dermal reactivity index. If a scheduled dose is missed, it is taken as soon as it is remembered, unless it is nearly time for the next dose, in which case the missed dose is skipped to maintain the single daily frequency.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Laritol

Evidence for Use in Allergic Rhinitis (Hay Fever and Perennial Allergies)

The primary research base for Laritol's active ingredient, Loratadine, includes numerous short-term Randomized Controlled Trials (RCTs). These studies were used in research exploring how symptoms change over time when compared against a placebo or active comparators in the class for outcomes related to sneezing, runny nose, and itchy eyes. Research examined outcomes related to physical discomfort and daily functioning during acute phases. The research has explored the use of the medicine in adults and adolescents, and to a more limited degree, in children aged 2 to 11 years with these same allergic symptoms.

Studies focused on short-term symptom changes, typically lasting between one and two weeks. Therefore, long-term outcomes and the sustained nature of the reported findings are not fully established over treatment periods exceeding one month. Comparative evidence is lacking to definitively assess how this specific medicine was evaluated against all newer second-generation agents in a consistent, head-to-head fashion for total symptom score outcomes.

Evidence for Use in Urticaria (Hives and Skin Itching)

Research also examined Laritol's active ingredient for use in conditions associated with Urticaria (hives), a condition marked by functional limitations. The main studies were RCTs designed to evaluate changes in symptoms related to inflammatory or irritative states. Studies explored patient-reported outcomes describing perceived discomfort, primarily measuring changes in pruritus (skin itching) scores and documenting the presence and size of wheals or welts.

Authoritative sources and systematic reviews contribute to the broader evidence landscape, reporting on the active ingredient's profile for these specific outcomes. Findings describe patterns observed in the studies over typical follow-up periods of two to four weeks. However, comparative evidence is lacking when assessing the medicine against all other available second-generation antihistamines specifically for patients with chronic urticaria.

Areas of Uncertainty and Research Gaps

The evidence quality varies across studies, and some key limitations persist in the research landscape. Certainty remains low regarding the full range of outcomes that may be relevant to the long-term management of chronic allergic disease, as follow-up durations were limited. Data for certain complex patient populations, such as older adults with significant coexisting health conditions, remain insufficient to describe findings reliably. The research provides context but not individual predictions, and studies help show what has been observed so far in controlled settings.

Key Studies & References

  1. BSACI guideline for the management of chronic urticaria and angioedema (Reference for Urticaria Management and Dose Titration)

Frequently Asked Questions (FAQ)

Common questions about Laritol (FAQ)

Q: How long does Laritol usually take to start working after the first dose?

Studies and official information indicate that relief from symptoms was reported to begin around 75 minutes after a dose of the tablet formulation. The duration of this effect is typically sustained for 24 hours.

Q: Does Laritol have the potential to make me feel drowsy or tired?

Laritol is classified as a non-sedating antihistamine. This classification means its potential for sedation is considered low, though drowsiness (somnolence) and fatigue remain common documented side effects in official safety documents.

Q: If I miss a dose of Laritol, does it change how the medicine works overall?

The official guidance for a missed dose focuses on maintaining the standard once-daily schedule. The guidance states that a double dose should not be taken to avoid potential increases in drug concentration. Adhering to the official dosing schedule is key to supporting the medicine’s overall effectiveness.

Q: Is Laritol generally considered suitable for older adults?

Research data for patients in this population are limited. Official guidance indicates the need for caution when the medicine is used in this population, particularly for those with coexisting health conditions.

Q: What kind of changes to laboratory tests might be linked to taking Laritol?

Official documents state that Laritol should be discontinued prior to allergy skin testing, as it can interfere with the diagnostic results of the test. Outside of this, clinical trials reported no clinically meaningful changes in standard laboratory values, though rare effects on hepatic (liver) function are documented.

Q: How does Laritol impact the immune system, based on research?

The official mechanism of action describes the drug’s function as altering the body’s response to histamine to help address the peripheral symptoms of inflammation. It does this by selectively blocking the histamine H1 receptor.

Q: What kind of studies support the use of Laritol for its main purpose?

The research supporting the medicine’s main uses (allergic rhinitis and hives) is derived from short-term controlled studies (clinical trials). These studies primarily evaluated changes in patient-reported symptom severity scores, such as measures of sneezing, itching, and the size of hives.

Q: Why is Laritol not recommended for people with certain kidney issues?

The need for a dosage adjustment in cases of severe renal impairment is due to the potential for active metabolites of the drug to accumulate in the body when kidney clearance is significantly reduced. This adjustment helps manage the systemic concentration of the drug.

Q: Why do official documents specify certain age restrictions for Laritol use?

The age restrictions are specified because the safety and effectiveness of the medicine have not been established through clinical research for use in children under the minimum approved age of two years.

Q: Does Laritol interact with common pain relievers like ibuprofen?

The official interaction documentation for Laritol focuses on medicines that affect specific liver enzymes. The regulatory interaction profile does not include any documented interactions with common non-steroidal anti-inflammatory pain relievers such as ibuprofen.

Q: Can Laritol interfere with the effectiveness of birth control pills?

Official regulatory interaction profiles for this medicine do not include any documented interactions that are known to interfere with the effectiveness of oral contraceptive medications (birth control pills).

Q: Does drinking alcohol while taking Laritol cause any specific safety concerns?

Studies conducted as part of the regulatory review process have indicated that the medicine does not appear to increase or potentiate the effects of alcohol when consumed.

Q: What are the known interactions between Laritol and herbal supplements?

A specific interaction is documented with the herbal product St. John’s Wort. This is because St. John’s Wort can affect the liver enzymes responsible for breaking down the medicine, which may alter the concentration of Laritol in the body.

Q: Is there a link between taking Laritol and feeling dizzy?

Regulatory safety information derived from clinical trials lists dizziness as an uncommon adverse reaction associated with the use of the medicine.

Q: Why is it important to share a complete list of all medications with the prescribing doctor before starting Laritol?

Official documents emphasize sharing all medicines, as Laritol has documented pharmacokinetic interactions (how the body processes the drug) with many other medications. These include drugs that affect specific liver enzymes, such as CYP3A4 and CYP2D6, which can change the medicine’s concentration in the body.

Q: Is it possible to develop a tolerance to Laritol over time?

Studies examining the pharmacokinetics (the body's action on the drug) have shown that the concentration of the drug and its active metabolite in the body is not altered by the duration of treatment. This finding supports the lack of pharmacokinetic tolerance.

How should Laritol be stored and disposed of?

How to Store and Dispose of Laritol

Laritol (loratadine) must be stored under specific environmental conditions as defined by regulatory labeling to maintain its stability.

Official Storage Requirements

The medication is required to be stored at Controlled Room Temperature, typically between 20 and 25C (68 to 77F). It must be protected from excessive moisture and kept out of the reach of children. The product must be stored in the container it came in and should not be frozen. Do not use tablets if the blister units appear torn or tampered with.

Official Disposal Instructions

Unused or expired Laritol should be disposed of using a drug take-back program whenever available. Since it is not on the FDA's flush list, if a take-back program is unavailable, the medicine should be mixed with an unappealing substance, placed in a sealed bag, and discarded with household trash. Personal information must be removed from the container label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Laritol found in:

A-Z Index: